The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration - An in vitro study of levofloxacin

被引:48
作者
Choi, G
Gomersall, CD [1 ]
Lipman, J
Wong, A
Joynt, GM
Leung, P
Ramsay, SJ
Ho, OM
机构
[1] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China
[2] Prince Wales Hosp, Intens Care Unit, Shatin, Hong Kong, Peoples R China
[3] Univ Queensland, Dept Anaesthesiol & Crit Care, Herston, Qld 4067, Australia
关键词
renal replacement therapy; anti-bacterial agents; quinolones; pharmacokinetics; kidney failure;
D O I
10.1016/j.ijantimicag.2004.06.005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We studied an in vitro model of continuous venous-venous haemofiltration (CVVH), into which levofloxacin 100 mg was infused, to determine levofloxacin adsorption and to determine the effect of filter material and point of dilution (pre- or post-filter) on sieving coefficient. Mean (standard deviation; S.D.) adsorption was 18.7 (5.3) mg for the polyamide filter and 40.2 (2.0) mg for the polyacrylonitrile (PAN) filter (P < 0.001). Post-dilution resulted in a minor, but statistically significant, decrease in sieving coefficient (pre-dilution 0.96 (S.D. 0.10), post-dilution 0.88 (S.D. 0.11) with the PAN filter. These data indicate that the variability in published values for levofloxacin sieving coefficient are not due to variation in point of dilution or membrane type (PAN or polyamide). Significant adsorption of levofloxacin onto PAN filters occurs. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:468 / 472
页数:5
相关论文
共 22 条
[1]   Clinical role of protein binding of quinolones [J].
Bergogne-Bérézin, E .
CLINICAL PHARMACOKINETICS, 2002, 41 (10) :741-750
[2]  
Böhler J, 1999, KIDNEY INT, V56, pS24
[3]  
BOPHLER J, 1999, KIDNEY INT S72, V56, pS24
[4]  
BOTTCHER S, 2004, J PHARM BIOMED ANAL, V25, P197
[5]   Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients [J].
Bugge, JF .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2001, 45 (08) :929-934
[6]   ESTIMATING SAMPLE SIZES FOR BINARY, ORDERED CATEGORICAL, AND CONTINUOUS OUTCOMES IN 2 GROUP COMPARISONS [J].
CAMPBELL, MJ ;
JULIOUS, SA ;
ALTMAN, DG .
BRITISH MEDICAL JOURNAL, 1995, 311 (7013) :1145-1148
[7]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[8]   Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients [J].
Guenter, SG ;
Iven, H ;
Boos, C ;
Bruch, HP ;
Muhl, E .
PHARMACOTHERAPY, 2002, 22 (02) :175-183
[9]   Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration [J].
Hansen, E ;
Bucher, M ;
Jakob, W ;
Lemberger, P ;
Kees, F .
INTENSIVE CARE MEDICINE, 2001, 27 (02) :371-375
[10]  
KRONFOL NO, 1987, T AM SOC ART INT ORG, V33, P300